Icatibant Ethypharm (Icatibant)

Icatibant is a competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary drivers of swelling in hereditary angioedema.

The prescribed dose is determined by the treating physician. Typically, a single 30 mg subcutaneous injection is administered for an acute HAE attack, with additional doses considered only under medical supervision based on clinical response.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

The main alternative class is plasma‑derived or recombinant C1‑inhibitor concentrates, which replace the deficient protein. Icatibant, by contrast, blocks the downstream bradykinin pathway, offering a rapid, protein‑free option that can be self‑administered subcutaneously.

Icatibant should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If refrigeration is unavailable for a short period, the product may be kept at controlled room temperature for up to 24 hours.

Icatibant is supplied as a sterile solution for subcutaneous injection. The injection is typically performed in the abdomen or thigh using a pre‑filled syringe, either by a healthcare professional or by the patient after appropriate training.

Serious adverse events include anaphylaxis, severe hypotension, and paradoxical worsening of angioedema. Patients should be monitored for signs of allergic reaction, sudden drop in blood pressure, or unexpected swelling, and seek immediate medical care if these occur.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients. Caution is advised for pregnant or breastfeeding women, and for patients receiving ACE inhibitors or ARBs due to an increased risk of angioedema.